Go Pro
NASDAQ:QNRX

Quoin Pharmaceuticals Q2 2026 Earnings Report

Quoin Pharmaceuticals logo
$7.26 -0.61 (-7.75%)
As of 09/4/2026 04:00 PM Eastern

Quoin Pharmaceuticals EPS Results

Actual EPS
-$1.90
Consensus EPS
-$1.61
Beat/Miss
Missed by -$0.29
One Year Ago EPS
N/A

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 14, 2026
Conference Call Time
9:30AM ET

Upcoming Earnings

Quoin Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules

Quoin Pharmaceuticals Earnings Headlines

Research Analysts Set Expectations for QNRX FY2026 Earnings
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX), Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

View Quoin Pharmaceuticals Profile